# Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Study · id `cardio:ct-nct06072001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06072001](<https://clinicaltrials.gov/study/NCT06072001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06072001

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 558 participants.

## Technical summary

Registry record NCT06072001. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-02 (actual); primary completion 2024-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 558 participants (planned count; ClinicalTrials.gov record NCT06072001, source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)
- Started: 2023-11-02 (actual) (ClinicalTrials.gov record NCT06072001, source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)
- Primary completion: 2024-09-30 (anticipated) (ClinicalTrials.gov record NCT06072001, source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT06072001, source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT06072001, source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06072001-2024-01-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
- Condition: Pain
- Condition: Pain Syndrome
- Condition: Pain, Chronic
- Condition: Chronic Pain
- Condition: Chronic Pain Syndrome
- Condition: Neuropathic Pain
- Condition: Central Neuropathic Pain
- Condition: Paraplegia
- Condition: Multiple Sclerosis
- Condition: Stroke
- Condition: Phantom Limb Syndrome With Pain
- Condition: Phantom Pain
- Condition: Traumatic Brain Injury
- Intervention (Drug): Adezunap (AP707)
- Intervention (Drug): Placebo
- Lead sponsor: Apurano Pharmaceuticals GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 6fb47683c7a4b90f1cf85e46b30e7cb17e86b4e96191900bb12aeedace110daa
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
